Ipragliflozin Fires First Shot In Japan SGLT2 Inhibitor Battle
This article was originally published in PharmAsia News
Executive Summary
Astellas and MSD have jointly launched in Japan the first SGLT2 inhibitor to reach the country’s market, with the commercialization of Suglat (ipragliflozin) on April 17 for the treatment of type 2 diabetes.